New Options, Emerging Combinations in Advanced Hepatocellular Carcinoma: Are Management Approaches Poised For Transformation?
Activity Description and Educational Objectives
The treatment landscape for intermediate and advanced hepatocellular carcinoma (HCC) is rapidly evolving with new approved systemic therapies and additional agents poised to enter the armamentarium. Combinations of agents or of systemic therapy with other treatment modalities are the next frontiers in the treatment of HCC. The advent of new and emerging treatment options has resulted in increasingly complex clinical decisions for the management of HCC.
In this activity based on a recent symposium at the American Society of Clinical Oncology’s 2018 Gastrointestinal Cancers Symposium (ASCO GI 2018), experts in HCC review the latest clinical data on approved and emerging systemic targeted therapies and immuno-oncology agents for the treatment of HCC, explain the underlying rationale for their therapeutic use in HCC, and provide practical strategies for safely and effectively incorporating new and evolving approaches into clinical practice.
Upon completion of this activity, participants should be better able to:
- Explain the rationale and mechanisms of action of approved and emerging systemic targeted therapies and immunotherapies for the treatment of advanced hepatocellular carcinoma
- Describe safety and efficacy data surrounding approved and emerging systemic targeted therapies and immunotherapies in advanced hepatocellular carcinoma
- Apply effective strategies to monitor and manage the unique adverse events associated with approved and emerging systemic targeted therapies and immunotherapies in advanced hepatocellular carcinoma
-
Develop appropriate treatment plans for patients with hepatocellular carcinoma, including enrollment in a clinical trial, taking into account disease- and patient-related factors
Target Audience
This activity has been designed to meet the educational needs of oncologists, interventional radiologists, hepatologists, and other clinicians involved in the management of patients with HCC.
Requirements for Successful Completion
In order to receive credit, participants must view the activity and complete the post-test and evaluation form. A score of 70% or higher is needed to obtain CME credit. There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.
Media: Enduring Material
Release and Expiration Dates: March 08, 2018 - March 07, 2019
Time to Complete: 90 minutes
Faculty & Disclosure / Conflict of Interest Policy
Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Medical Learning Institute, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The associates of Medical Learning Institute, Inc., the accredited provider for this activity, and PVI, PeerView Institute for Medical Education do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME activity during the past 12 months.
Course Director and Moderator
Ghassan Abou-Alfa, MD, MBA
Attending
Memorial Sloan Kettering Cancer Center
New York, New York
Ghassan Abou-Alfa, MD, MBA, has a financial interest/relationship or affiliation in the form of:
Consultant for Agios Pharmaceuticals; Amgen; Aptus Pharmaceuticals, Inc.; ASLAN Pharmaceuticals; Astellas Pharma Inc.; AstraZeneca; Bayer; Bristol-Myers Squibb; Boston Scientific Corporation; CARsgen Therapeutics; CASI Pharmaceuticals, Inc.; Celgene Corporation; CytomX Therapeutics; Daiichi Sankyo; Debiopharm Group; Delcath Systems Inc.; Eisai Inc.; F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; Halozyme, Inc.; Inovio Pharmaceuticals, Inc.; Ipsen; Merck & Co., Inc.; MedImmune; Onxeo; PCI Biotech; sanofi-aventis; Servier; Silenseed; SillaJen Inc; Sirtex; and Yakult Pharmaceutical Industry.
Grant/Research Support from Agios Pharmaceuticals; Array BioPharma; AstraZeneca; Bayer; Bristol-Myers Squibb; CASI Pharmaceuticals, Inc.; Celgene Corporation; Exelixis; F. Hoffmann-La Roche Ltd.; Genentech, Inc.; Incyte Corporation; Lilly; MabVax Therapeutics Holdings, Inc.; MedImmune; Momenta Pharmaceuticals; Novartis Pharmaceuticals Corporation; and OncoMed Pharmaceuticals. (Research support to Institution)
Ghassan Abou-Alfa, MD, MBA, does intend to discuss either non–FDA-approved or investigational use for the following products/devices: multi-kinase inhibitors including but not limited to cabozantinib, lenvatinib, regorafenib; other targeted agents; immune checkpoint inhibitors targeting PD-1/PD-L1 or CTLA-4 as well as other immune-based strategies potentially useful for the treatment of hepatocellular carcinoma.
Faculty
Anthony El-Khoueiry, MD
Associate Professor of Clinical Medicine
Medical Director of Clinical Investigations Support Office
Phase I Program Director
USC Norris Comprehensive Cancer Center
Los Angeles, California
Anthony El-Khoueiry, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for Bayer HealthCare Pharmaceuticals, Inc. and Bristol-Myers Squibb.
Advisory Board for AstraZeneca; Bayer HealthCare Pharmaceuticals, Inc.; Bristol-Myers Squibb; CytomX Therapeutics; Eisai Inc.; F. Hoffmann-La Roche/Genentech, Inc.; and Novartis Pharmaceuticals Corporation.
Anthony El-Khoueiry, MD, does intend to discuss either non–FDA-approved or investigational use for the following products/devices: multi-kinase inhibitors including but not limited to cabozantinib, lenvatinib, regorafenib; other targeted agents; immune checkpoint inhibitors targeting PD-1/PD-L1 or CTLA-4 as well as other immune-based strategies potentially useful for the treatment of hepatocellular carcinoma.
Richard S. Finn, MD
Associate Professor of Medicine
Division of Hematology/Oncology
Geffen School of Medicine at UCLA
Los Angeles, California
Richard S. Finn, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for Bayer HealthCare Pharmaceuticals Inc.; Bristol-Myers Squibb; Eisai Inc.; Novartis Pharmaceuticals Corporation; and Pfizer Inc.
Richard S. Finn, MD, does intend to discuss either non–FDA-approved or investigational use for the following products/devices: multi-kinase inhibitors including but not limited to cabozantinib, lenvatinib, regorafenib; other targeted agents; immune checkpoint inhibitors targeting PD-1/PD-L1 or CTLA-4 as well as other immune-based strategies potentially useful for the treatment of hepatocellular carcinoma.
CME Reviewer
Steve S. Choi, MD
Duke University Medical Center
Durham, North Carolina
Steve S. Choi, MD, has no financial interests/relationships or affiliations in relation to this activity.
Medical Director
Marie Becker, PhD
PVI, PeerView Institute for Medical Education
Marie Becker, PhD, has no financial interests/relationships or affiliations in relation to this activity.
Disclaimer
The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.
Providership, Credit & Support
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.
The Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Providership
This CME activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.
Support
This educational activity is supported through medical education grants from Bristol-Myers Squibb, Eisai Inc., and Exelixis, Inc.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.
No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.
The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.
About This CME Activity
PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.
Copyright © 2000-2018, PeerView